A Phase I/II study of ONO-5163 in patients with secondary hyperparathyroidism under maintenance dialysis (ONO-5163-02)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2020 Results of meta-analysis of four studies (NCT01785849, NCT01254565, JapicCTI142664 & JapicCTI121978) assessing efficacy and safety of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis, published in the Clinical Nephrology.
01 Aug 2017 Results (n=24) of phase II of the study assessing efficacy, published in the Clinical Nephrology.
29 Jun 2016 Planned number of patients changed from 55 to 61.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com